<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745170</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308E301</org_study_id>
    <nct_id>NCT03745170</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer</brief_title>
  <official_title>Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate overall survival of Sintilimab+ oxaliplatin +&#xD;
      capecitabine and placebo+ oxaliplatin + capecitabine, as first-line treatment for advanced&#xD;
      gastric or gastroesophageal junction (GEJ) adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Overall survival (OS)of Sintilimab in combination with oxaliplatin + fluoropyrimidine versus placebo+oxaliplatin + fluoropyrimidine in all randomized participants;Overall survival(OS) of Sintilimab + oxaliplatin + capecitabine versus placebo+ oxaliplatin + capecitabine in participants with programmed cell death ligand 1 (PD-L1) expressing tumors (CPS&gt;=10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survivla (PFS)</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Progression Free Survivla (PFS) of Sintilimab in combination with oxaliplatin + fluoropyrimidine versus placebo+oxaliplatin + fluoropyrimidine in all randomized participants and PD-L1 expression participants(CPS&gt;=10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Duration of Response (DoR) of Sintilimab in combination with oxaliplatin + fluoropyrimidine versus placebo+oxaliplatin + fluoropyrimidine in all randomized participants and PD-L1 expression participants(CPS&gt;=10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Objective Response Rate (ORR) of Sintilimab in combination with oxaliplatin + fluoropyrimidine versus placebo+oxaliplatin + fluoropyrimidine in all randomized participants and PD-L1 expression participants(CPS&gt;=10) per RESIST v1,1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Disease Control Rate (DCR) of Sintilimab + oxaliplatin + capecitabine versus placebo+ oxaliplatin + capecitabine in in all randomized participants . and PD-L1 expression participants(CPS&gt;=10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing clinical and laboratory adverse events (AEs)</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Safety of Sintilimab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in all randomized participants and PD-L1 expression participants(CPS&gt;=10)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Sintilimab+ Oxaliplatin +capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo +Oxaliplatin + Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Weight&lt;60Kg: 3mg/kg Q3W Weignt&gt;=60Kg:200 mg Q3W on Day 1 by IV infusion</description>
    <arm_group_label>Sintilimab+ Oxaliplatin +capecitabine</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m^2 Q3W on Day 1 by IV infusion</description>
    <arm_group_label>Sintilimab+ Oxaliplatin +capecitabine</arm_group_label>
    <arm_group_label>placebo +Oxaliplatin + Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000 mg/m^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14</description>
    <arm_group_label>Sintilimab+ Oxaliplatin +capecitabine</arm_group_label>
    <arm_group_label>placebo +Oxaliplatin + Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Weight&lt;60Kg: 3mg/kg Q3W Weignt&gt;=60Kg:200 mg Q3W on Day 1 by IV infusion</description>
    <arm_group_label>placebo +Oxaliplatin + Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has histologically confirmed diagnosis of unresectable locally advanced,recurrent or&#xD;
             metastatic gastric or GEJ adenocarcinoma.&#xD;
&#xD;
          -  Male or Female at least 18 years and younger than 75 yeas of age&#xD;
&#xD;
          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Did not receive neoadjuvant or adjuvant treatment (chemotherapy, radiotherapy, or&#xD;
             both) for their disease within the last 6 months&#xD;
&#xD;
          -  Must agree to provide tumor tissue sample, either from a previous surgery or biopsy ,&#xD;
             within 6 months or fresh, prior to the start of treatment in this study and Has a&#xD;
             PD-L1 status determined by immunohistochemistry (IHC) at a central laboratory&#xD;
&#xD;
          -  Has measurable or non-measurable (but assessable) disease as defined by RECIST 1.1 as&#xD;
             determined by investigator assessment.&#xD;
&#xD;
          -  Has adequate organ function.&#xD;
&#xD;
          -  Expected survival&gt;=12 weeks.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy&#xD;
             test at the timing of enrollment&#xD;
&#xD;
          -  Participants of childbearing potential must be willing to use an adequate method of&#xD;
             contraception for the course of the study through 6 months after the last dose of&#xD;
             study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suspicious active bleeding or obstruction phenomenon and Has difficulty in swallow&#xD;
             tablets and food&#xD;
&#xD;
          -  HER2-positive status&#xD;
&#xD;
          -  Has had previous therapy for unresectable locally advanced, recurrent or metastatic&#xD;
             gastric/GEJ cancer&#xD;
&#xD;
          -  Liver metastasis lesion&gt;=50% of liver volume&#xD;
&#xD;
          -  Has received prior therapy with a dose of cisplatin&gt;=300 mg/m-^2&#xD;
&#xD;
          -  Has grade â‰¥ 2 peripheral sensory neuropathy&#xD;
&#xD;
          -  Known DPD enzyme deficiency status (&gt;=grade 3 mucosal toxicity in previous&#xD;
             fluorouracil treatment)&#xD;
&#xD;
          -  Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, anti-PD&#xD;
             L2 , anti-CD137,anti-CTLA-4 agent or with an agent directed to another stimulatory or&#xD;
             co-inhibitory T-cell receptor&#xD;
&#xD;
          -  Is currently participating in and receiving study therapy ,except those in the&#xD;
             survival follow up period of an investigational agent study or non-interventional&#xD;
             study .&#xD;
&#xD;
          -  Received systemic treatment with corticosteroids (&gt; 10 mg daily prednisone equivalent)&#xD;
             or other immunosuppressive medications within 4 weeks of first dose. Inhaled or&#xD;
             topical steroids ,adrenal replacement steroid doses and steroid of prevention allergic&#xD;
             reaction of i.v. contrast agent are permitted in the absence of active autoimmune&#xD;
             disease.&#xD;
&#xD;
          -  Received a live vaccine within 4 weeks of the first dose of study medication or plan&#xD;
             to receive live vaccine during study period.&#xD;
&#xD;
          -  Has had major surgery (craniotomy, thoracotomy or laparotomy) within 4 weeks prior to&#xD;
             first dose of study medication, or anticipation of the need for major surgery during&#xD;
             the course of study treatment&#xD;
&#xD;
          -  Known symptomatic central nervous system (CNS) metastasis and/or carcinomatous&#xD;
             meningitis. Subjects received prior treatment and have stable disease more than 4&#xD;
             weeks from first dose of study medication.&#xD;
&#xD;
          -  Clinical significant ascites, including which can be detected in percussion, had been&#xD;
             ever drained or still need to be controlled currently.&#xD;
&#xD;
          -  Bilateral moderate pleural effusion, or a large amount of pleural effusion on one&#xD;
             side, or has caused respiratory dysfunction requiring drainage.&#xD;
&#xD;
          -  Bone metastasis with risk of paraplegia.&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease or has a history of the disease within&#xD;
             the last 2 years (subjects with vitiligo, psoriasis, alopecia or Grave's disease,&#xD;
             residual hypothyroidism due to autoimmune thyroiditis only requiring hormone&#xD;
             replacement, or type I diabetes mellitus only requiring insulin replacement, but not&#xD;
             required systemic treatment in the last 2 years, are permitted to enroll) .&#xD;
&#xD;
          -  Known primary immunodeficiency.&#xD;
&#xD;
          -  Known active tuberculosis.&#xD;
&#xD;
          -  Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation.&#xD;
&#xD;
          -  Known&gt;=grade 3 allergy or hypersensitivity to oxaliplatin,capecitabine or any&#xD;
             monoclonal antibodies.&#xD;
&#xD;
          -  Human Immunodeficiency Virus (HIV) infection (HIV antibody positive).&#xD;
&#xD;
          -  Active or poorly controlled severe infection.&#xD;
&#xD;
          -  Symptomatic congestive heart failure (New York Heart Association grade II-IV) or&#xD;
             symptomatic, poorly controlled arrhythmia.&#xD;
&#xD;
          -  Poorly controlled arterial hypertension (SBP â‰¥ 160mmHg or DBP â‰¥ 100mmHg) with standard&#xD;
             treatment .&#xD;
&#xD;
          -  Prior arterial thromboembolism event, including myocardial infarction, unstable&#xD;
             angina, stroke and transient ischemic attack, within 6 months of enrollment.&#xD;
&#xD;
          -  Malnutrition requiring intravenous nutrition, subjects with malnutrition correctionâ‰¥4&#xD;
             weeks are permitted to enroll.&#xD;
&#xD;
          -  Prior deep vein thrombosis, pulmonary embolism or any other severe thromboembolism&#xD;
             events (implanted port or catheter caused thrombosis, or superficial vein thrombosis&#xD;
             are not considered as severe thromboembolism) within 3 months before enrollment.&#xD;
&#xD;
          -  History of uncontrolled metabolic disorder, non-malignant organ or systemic disease or&#xD;
             secondary carcinomatous reaction, with high medical risk and/or uncertainty of life&#xD;
             expectancy evaluation.&#xD;
&#xD;
          -  With hepatic encephalopathy, hepatorenal syndrome or hepatic cirrhosis of Child-Pugh&#xD;
             grade B or higher.&#xD;
&#xD;
          -  History of intestinal obstruction or the following diseases: inflammatory bowel&#xD;
             disease or extensive bowel resection (partial colonic resection or extensive small&#xD;
             bowel resection, concomitant with chronic diarrhea), Crohn's disease, ulcerative&#xD;
             colitis.&#xD;
&#xD;
          -  Known acute or chronic active hepatitis B infection (positive HBsAg and HBV DNA â‰¥ 200&#xD;
             IU/mL or â‰¥ 10^3 copies/mL positive) infection or acute or chronic active hepatitis C&#xD;
             (HCV antibody positive and HCV RNA positive) infection.&#xD;
&#xD;
          -  History of gastrointestinal perforation and /or fistula within 6 months before&#xD;
             enrollment.&#xD;
&#xD;
          -  Subjects with interstitial lung disease requiring steroids therapy.&#xD;
&#xD;
          -  Other primary malignancy, with the exception of:&#xD;
&#xD;
               1. Malignancy which achieved complete response for at least 2 years before&#xD;
                  enrollment and do not need other treatment during study period;Curative&#xD;
                  malignancy, without active disease in the last 5 years and with very low&#xD;
                  recurrence risk;&#xD;
&#xD;
               2. Non-melanoma skin cancer or malignant freckle-like nevus with adequate treatment&#xD;
                  and no evidence of recurrence ;&#xD;
&#xD;
               3. Adequately treated in-situ carcinoma.&#xD;
&#xD;
          -  Women who are pregnant or nursing.&#xD;
&#xD;
          -  Other acute or chronic diseases, mental illness, or abnormal laboratory test results&#xD;
             that may lead to the following outcomes: increase the risk of participating in study&#xD;
             or study drug administration, or interfere with the interpretation of the study&#xD;
             results and considered by investigator as &quot;NOT&quot; eligible to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mengmeng Ci</last_name>
    <phone>8613911509423</phone>
    <email>mengmeng.ci@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>People's Liberation Army No. 307 Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianming Xu</last_name>
      <phone>+86010-66947176</phone>
      <email>Jianmingxu2014@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

